Celltech and American Cyanamid
Executive Summary
Lederle parent is Celltech's partner in a cancer research agreement. Lederle will shepherd through clinical trials, FDA review, and marketing any products developed by the British research firm. Celltech will receive $7.5 mil. initially for two years "to develop a new approach to antibody cancer imaging and therapy using" second generation "monoclonal antibodies," Celltech announced ("The Pink Sheet" April 14, In Brief).
You may also be interested in...
Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.
UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
EU Industry Decries Price Cuts And Clawbacks
A detailed report published by Medicines for Europe setting out policies affecting the off-patent industry across 22 European countries demonstrates the urgent need for pricing and reimbursement and procurement reforms, the association insists.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: